Home › NDC Lookup › Ingredients › Prednisone › 60219-1707-01
prednisone 10 mg Tablet, 100-count — NDC 60219-1707-01 package photo

prednisone 10 mg Tablet, 100-count

by Amneal Pharmaceuticals NY LLC · 100 TABLET in 1 BOTTLE, PLASTIC (60219-1707-1)
NDC 60219-1707-01
🏷️ FDA NDC (as labeled) 60219-1707-1 billing pads the package segment with a zero
This package
Contains100-count Cost per ea$0.0533 NADAC Per package$5.33 / 100 tablets Pack sizes3 compare ↓
Also priced by: Medicaid pays $0.3021/unit · Part D plans $0.2837/unit — full pricing hub ↓
Also comes in: 100 tablets 60219-1707-03 500 tablets 60219-1707-05
Rx only Generic On market Non-controlled
🗂️ Data synced Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

🆔 Identity & classification

FDA NDC (as labeled) 60219-1707-1
Product NDC 60219-1707
11-digit billing NDC 60219170701
NCPDP billing unit EA — each (per item)
RxCUI 198145, 312615
UNII VB0R961HZT
UPC 0360219170759, 0360219170711, 0360219170858, 0360219170810 +2 more
Application # ANDA213386
SPL Set ID 03228706-92b9-43c9-8d73-c73aa124c58d
Established class (EPC) Corticosteroid
Mechanism of action Corticosteroid Hormone Receptor Agonists
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2020-06-24
Route ORAL
Dosage form TABLET
Substance PREDNISONE
GPI-14 22100045000320
GCN Seq No 006749
GCN 27172
HICL code 002879
Ingredient (HICL) Prednisone
HIC1 code P
Therapeutic class — broad (HIC1) Endocrine System
HIC2 code P5
Therapeutic class — intermediate (HIC2) Adrenocortical Hormones
HIC3 code P5A
Therapeutic class — specific (HIC3) Glucocorticoids
AHFS code 68:04.00.00
AHFS class Adrenals
FDB label name PREDNISONE 10 MG TABLET
FDB brand name Prednisone
Legend status F — Federal legend — prescription drug or device
TE code (Orange Book) AB · RLD · RS
Why two NDCs? The FDA registers this code as 60219-1707-1 — a 5-4-1 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the package segment → 60219-1707-01. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

🏷️ RxNorm drug class

This medicine belongs to the Corticosteroid class.

Pharmacologic class Corticosteroid
Drug family (ATC) Corticosteroids acting locally, Glucocorticoids
How it works Corticosteroid Hormone Receptor Agonists
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

🏭 Manufacturer & labeler

LabelerAmneal Pharmaceuticals NY LLC
Application holderAMNEAL EU LTD
FDA applicationANDA213386 (ANDA)
Labeler code60219
First marketedJun 2020
Product typeHuman Prescription Drug
Portfolio372 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

🩺 Clinical

Label name PREDNISONE 10 MG TABLET Ingredient Prednisone
📖 What it is MedlinePlus · NLM

Prednisone is used alone or with other medications to treat the symptoms of low corticosteroid levels (lack of certain substances that are usually produced by the body and are needed for normal body functioning). Prednisone is also used to treat other conditions in patients with normal corticosteroid levels. These conditions include certain types of arthritis; severe allergic reactions; multiple sclerosis (a disease in which the nerves do not function properly); lupus (a disease in which the body attacks many of its own organs); and certain conditions that affect the lungs, skin, eyes, kidneys...

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • Prednisone calms down your immune system and reduces inflammation in your body. It's used for a huge range of conditions — everything from asthma and severe allergies to Crohn's di...
  • Why did my doctor put me on prednisone — what does it actually do?
  • Yes, morning really does matter — your body naturally produces its own cortisol hormone between 2 a.m. and 8 a.m., and taking prednisone at that time works with your body's rhythm...
  • Do I really have to take it in the morning? And does it matter if I take it with food?
📖 Read our full Prednisone guide →
8
Nutrient depletion considerations

Prednisone may be associated with lower levels of 8 nutrients — worth a chat with your pharmacist, not a cause for alarm.

🧪 Full Prednisone nutrient depletion report →
An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

💊 What it looks like

Color white
ShapeRound
ImprintAC72
Size9 mm
ScoringScored — splits in 2
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

🧪 Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII EWQ57Q8I5X
    Lactose monohydrate is a natural sugar derived from milk. It serves as a filler and binder in tablets and capsules, helping create the proper size, texture, and consistency of the medicine.
  • UNII 70097M6I30
    Magnesium stearate is a salt made from magnesium and stearic acid, a fatty substance. It's used in tablets and capsules as a lubricant and glidant to help ingredients flow smoothly during manufacturing and prevent sticking.
  • UNII PNR0YF693Y
    A plant-based powder made from purified wood cellulose. It acts as a filler to add bulk, a binder to hold ingredients together, and a disintegrant to help the tablet break apart in the stomach.
  • UNII 5856J3G2A2
    A starch-based powder made from potatoes and processed with sodium. It acts as a disintegrant, helping the tablet or capsule break apart quickly in the stomach so the medicine can be absorbed.
  • UNII O8232NY3SJ
    A plant-based carbohydrate derived from corn kernels. It acts as a filler to add bulk, a binder to hold ingredients together, and a disintegrant to help the tablet break apart in your stomach for absorption.

5 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

💲 Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.053 $5.33 / 100 tablets
Medicaid paysCMS SDUD · 12 mo $0.3021 $30.21 / 100 tablets
Medicare drug plans payPart D · Q2 2026 $0.2837 $28.37 / 100 tablets
Medicare Part B allowsASP · J7512 $0.004 / J7512 unit —
NADAC price history (per ea) — tap or hover for the price & month
Jan 2022 Aug 2022 Jan 2026 Sep 2026 $0.075 $0.053
▼ Down 29% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

🧾 Billing & reimbursement

FDA NDC (as labeled)60219-1707-1
11-digit billing NDC60219-1707-01
Format5-4-1 as registered → padded to 5-4-2 for billing (zero added to the package segment)
HCPCS J-codeJ7512
DescriptorPREDNISONE, IMMEDIATE RELEASE OR DELAYED RELEASE, ORAL, 1 MG
Billing units / pkg10 units
Crosswalk sourcePDAC NDC-HCPCS crosswalk (DME MAC / DMEPOS)
Where does this data come from?
The HCPCS J-code crosswalk comes from the CMS ASP NDC-HCPCS crosswalk and the DMEPDAC (DME MAC) NDC-HCPCS crosswalk — free public CMS data. Billing units are derived from the code’s descriptor and the package amount.

🔁 Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
PredniSONE 10 mg 00054-9817-25 Hikma 100 tablets $0.053 AB Availability likely —
Prednisone 10 mg 00378-0641-01 Mylan 100 tablets $0.053 — Availability likely —
Prednisone 10 mg 00591-5442-01 Actavis 100 tablets $0.053 — Availability likely —
Prednisone 10 mg 00904-6923-61 Major 100 tablets $0.053 AB Availability likely —
Prednisone 10 mg 59651-0487-01 Aurobindo 100 tablets $0.053 AB Availability likely —
prednisone 10 mgthis 60219-1707-01 Amneal 100 tablets $0.053 AB Availability likely —
Prednisone 10 mg 60687-0134-01 American 100 tablets $0.053 AB Availability likely —
Prednisone 10 mg 60687-0914-01 American 100 tablets $0.053 AB Availability likely —
PredniSONE Tablets, USP, 10 mg 63561-0121-01 Granulation 100 tablets $0.053 AB Availability likely —
Prednisone 10 mg 70954-0059-10 ANI 100 tablets $0.053 AB Availability likely —
PredniSONE 10 mg 00054-0017-20 Hikma 100 tablets $0.060 AB FDA listed +14%
Prednisone 10 mg 00603-5338-15 Par 21 tablets $0.585 AB Availability likely +998%
prednisone 10 mg 00615-8440-05 NCS 15 tablets — AB FDA listed —
Prednisone 10 mg 10135-0777-01 Marlex 100 tablets — AB FDA listed —
PredniSONE 10 mg 42708-0045-21 QPharma, 21 tablets — — FDA listed —
Prednisone 10 mg 42708-0115-21 QPharma, 21 tablets — AB FDA listed —
prednisone 10 mg 42708-0166-21 QPharma 21 tablets — AB FDA listed —
Prednisone 10 mg 50090-3137-00 A-S 10 tablets — AB FDA listed —
Prednisone 10 mg 50090-5202-00 A-S 60 tablets — AB FDA listed —
Prednisone 10 mg 50090-7023-00 A-S 100 tablets — AB FDA listed —
Prednisone 10 mg 50090-7024-00 A-S 10 tablets — AB FDA listed —
Prednisone 10 mg 50090-7025-00 A-S 60 tablets — AB FDA listed —
prednisone 10 mg 50090-7218-00 A-S 10 tablets — AB FDA listed —
prednisone 10 mg 50090-7219-00 A-S 60 tablets — AB FDA listed —
prednisone 10 mg 50090-7369-00 A-S 10 tablets — AB FDA listed —
prednisone 10 mg 50090-7371-00 A-S 60 tablets — AB FDA listed —
Prednisone 10 mg 51407-0922-10 Golden 1000 tablets — — FDA listed —
Prednisone 10 mg 51655-0410-20 Northwind 20 tablets — AB FDA listed —
PredniSONE 10 mg 51655-0493-49 Northwind 42 tablets — — FDA listed —
Prednisone 10 mg 51655-0935-20 Northwind 20 tablets — — FDA listed —
Prednisone 10 mg 54348-0506-10 PharmPak, 10 tablets — AB FDA listed —
Prednisone 10 mg 55154-3564-00 Cardinal 10 tablets — AB FDA listed —
Prednisone 10 mg 63187-0037-05 Proficient 5 tablets — AB FDA listed —
Prednisone 10 mg 63187-0300-05 Proficient 5 tablets — AB FDA listed —
Prednisone 10 mg 63629-2257-01 Bryant 1000 tablets — AB FDA listed —
prednisone 10 mg 64380-0784-01 Strides 100 tablets — AB FDA listed —
Prednisone 10 mg 66267-0171-15 NuCare 15 tablets — AB FDA listed —
Prednisone 10 mg 66267-0812-10 NuCare 100 tablets — AB FDA listed —
prednisone 10 mg 67046-1579-03 Coupler 30 tablets — AB FDA listed —
Prednisone 10 mg 67296-0140-01 Redpharm 10 tablets — AB Discontinued —
Prednisone 10 mg 68071-2661-00 NuCare 10 tablets — AB FDA listed —
Prednisone 10 mg 68071-3641-01 NuCare 10 tablets — AB FDA listed —
Prednisone 10 mg 68071-3746-00 NuCare 10 tablets — AB FDA listed —
Prednisone 10 mg 68071-3821-03 NuCare 30 tablets — AB FDA listed —
prednisone 10 mg 68788-8166-02 Preferred 21 tablets — AB FDA listed —
prednisone 10 mg 70518-3476-00 REMEDYREPACK 21 tablets — AB Discontinued —
prednisone 10 mg 70518-4038-00 REMEDYREPACK 48 tablets — AB FDA listed —
PredniSONE 10 mg 70518-4191-01 REMEDYREPACK 30 tablets — — FDA listed —
prednisone 10 mg 70518-4354-00 REMEDYREPACK 30 tablets — AB FDA listed —
Prednisone 10 mg 70518-4560-00 REMEDYREPACK 18 tablets — AB FDA listed —
prednisone 10 mg 70518-4660-00 REMEDYREPACK 14 tablets — AB FDA listed —
Prednisone 10 mg 71205-0362-05 Proficient 5 tablets — AB FDA listed —
Prednisone 10 mg 71205-0421-10 Proficient 10 tablets — AB FDA listed —
prednisone 10 mg 71205-0729-10 Proficient 10 tablets — AB FDA listed —
prednisone 10 mg 71205-0818-05 Proficient 5 tablets — AB FDA listed —
Prednisone 10 mg 71335-0335-00 Bryant 10 tablets — AB Discontinued —
prednisone 10 mg 71335-2069-00 Bryant 10 tablets — AB FDA listed —
prednisone 10 mg 71335-2122-01 Bryant 5 tablets — AB FDA listed —
PredniSONE Tablets, USP, 10 mg 71335-2736-00 Bryant 12 tablets — AB FDA listed —
PredniSONE Tablets, USP, 10 mg 71335-2752-00 Bryant 10 tablets — AB FDA listed —
PredniSONE Tablets, USP, 10 mg 71335-3044-01 Bryant 100 tablets — AB FDA listed —
PredniSONE Tablets, USP, 10 mg 71335-3045-01 Bryant 1000 tablets — AB FDA listed —
PredniSONE Tablets, USP, 10 mg 72162-2485-00 Bryant 1000 tablets — AB FDA listed —
Prednisone 10 mg 72189-0589-10 Direct_Rx 10 tablets — AB FDA listed —
Prednisone 10 mg 72789-0401-10 PD-Rx 10 tablets — AB FDA listed —
PredniSONE Tablets, USP, 10 mg 72789-0475-01 PD-Rx 100 tablets — AB FDA listed —
PredniSONE Tablets, USP, 10 mg 72789-0513-10 PD-Rx 10 tablets — AB FDA listed —
Prednisone 10 mg 76420-0068-20 Asclemed 20 tablets — AB FDA listed —
prednisone 10 mg 76420-0412-00 Asclemed 1000 tablets — AB FDA listed —
Prednisone 10 mg 80425-0193-01 Advanced 21 tablets — AB FDA listed —
prednisone 10 mg 80425-0484-01 Advanced 21 tablets — AB FDA listed —
PredniSONE 10 mg 80425-0485-01 Advanced 21 tablets — — FDA listed —
Prednisone 10 mg 80425-0491-01 Advanced 21 tablets — AB FDA listed —
prednisone 10 mg 85766-0001-00 Sportpharm 1000 tablets — AB FDA listed —
Prednisone 10 mg 87063-0044-01 ASCLEMED 100 tablets — AB FDA listed —
Prednisone 10 mg 50090-1001-00 A-S 21 tablets — AB FDA listed —
Prednisone 10 mg 50090-1002-00 A-S 48 tablets — AB Discontinued —
PredniSONE 10 mg 55289-0330-05 PD-Rx 5 tablets — — FDA listed —
prednisone 10 mg 51655-0972-20 Northwind 20 tablets — AB FDA listed —
PredniSONE 10 mg 51655-0726-21 Northwind 21 tablets — AB FDA listed —
prednisone 10 mg 87441-0069-01 Unit 30 tablets — AB FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

⏳ Availability & generic status

🏛️
2020
On the market since
Jun 2020
📍
2026
Currently FDA-listed
6 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

🗺️ Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for 60219-1707-01, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
132.9K
Units reimbursed last 4 qtrs
3.6M
Gross reimbursed last 4 qtrs
$1.09M
Avg / prescription
$8.18
Avg / unit
$0.3021
Latest quarter Q1 2026
35.1KRx
Medicaid pays / ea
$0.3021
gross reimbursed
vs
NADAC / ea
$0.0533
acquisition cost
=
Spread
+$0.2488
+467% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
46% FFS 54% MCO
Fee-for-service · 61,549 Rx Managed care · 71,386 Rx
State Medicaid map
Alaska: 3,500 units · 477 per 100k residents AK Maine: 5,679 units · 407 per 100k residents ME Washington: 88,448 units · 1,132 per 100k residents WA Idaho: 14,174 units · 722 per 100k residents ID Montana: 8,666 units · 766 per 100k residents MT North Dakota: 2,338 units · 299 per 100k residents ND Minnesota: 23,491 units · 409 per 100k residents MN Wisconsin: 21,288 units · 360 per 100k residents WI Michigan: 93,878 units · 935 per 100k residents MI New York: 57,703 units · 295 per 100k residents NY Vermont: no data reported VT New Hampshire: 1,745 units · 124 per 100k residents NH Oregon: 51,948 units · 1,227 per 100k residents OR Nevada: 123,835 units · 3,877 per 100k residents NV Wyoming: 669 units · 115 per 100k residents WY South Dakota: no data reported SD Iowa: 8,091 units · 252 per 100k residents IA Illinois: 33,361 units · 266 per 100k residents IL Indiana: 44,494 units · 648 per 100k residents IN Ohio: 97,478 units · 827 per 100k residents OH Pennsylvania: 61,378 units · 474 per 100k residents PA New Jersey: 16,242 units · 175 per 100k residents NJ Massachusetts: 10,671 units · 152 per 100k residents MA California: 1,439,014 units · 3,693 per 100k residents CA Utah: 11,020 units · 323 per 100k residents UT Colorado: 24,312 units · 414 per 100k residents CO Nebraska: 6,297 units · 318 per 100k residents NE Missouri: 25,519 units · 412 per 100k residents MO Kentucky: 78,904 units · 1,743 per 100k residents KY West Virginia: 32,431 units · 1,832 per 100k residents WV Virginia: 39,877 units · 458 per 100k residents VA Maryland: 17,500 units · 283 per 100k residents MD Connecticut: 8,252 units · 228 per 100k residents CT Rhode Island: 893 units · 81.6 per 100k residents RI Arizona: 167,672 units · 2,256 per 100k residents AZ New Mexico: 11,245 units · 532 per 100k residents NM Kansas: 11,017 units · 375 per 100k residents KS Arkansas: 18,216 units · 594 per 100k residents AR Tennessee: 18,440 units · 259 per 100k residents TN North Carolina: 57,014 units · 526 per 100k residents NC South Carolina: 21,063 units · 392 per 100k residents SC Delaware: 1,073 units · 104 per 100k residents DE Oklahoma: 27,263 units · 673 per 100k residents OK Louisiana: 57,080 units · 1,248 per 100k residents LA Mississippi: 24,032 units · 817 per 100k residents MS Alabama: 27,808 units · 544 per 100k residents AL Georgia: 48,605 units · 441 per 100k residents GA D.C.: 2,095 units · 309 per 100k residents DC Hawaii: 60,516 units · 4,217 per 100k residents HI Texas: 189,939 units · 623 per 100k residents TX Florida: 389,554 units · 1,723 per 100k residents FL
Units reimbursed · per 100k residents
81.64,217
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Hawaii 4,217 /100k
2 Nevada 3,877 /100k
3 California 3,693 /100k
4 Arizona 2,256 /100k
5 West Virginia 1,832 /100k
6 Kentucky 1,743 /100k
7 Florida 1,723 /100k
8 Louisiana 1,248 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

💊 Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
100 tablets this page60219-1707-01 132,935 Rx · $1,087,418
500 tablets60219-1707-05 90,060 Rx · $702,901
100 tablets60219-1707-03 No Medicaid data
Drug total (last 4 qtrs): 222,995 Rx · 6,098,045 units · $1,790,319 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

📊 Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Prednisone — the program that covers self-administered drugs. 17 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Prednisone. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$16.74M
Claims incl. refills
4.1M
Beneficiaries
3M
Spend / beneficiary
$5.57
Spend / claim
$4.04
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

📦 Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startStatus
60219-1707-01 You're viewing this 100 TABLET in 1 BOTTLE, PLASTIC (60219-1707-1) $0.0533 / ea $5.33 2020-06-24 Active
60219-1707-03 10 BLISTER PACK in 1 CARTON (60219-1707-3) / 10 TABLET in 1 BLISTER PACK (60219-1707-2) — — 2020-06-24 Active
60219-1707-05 500 TABLET in 1 BOTTLE, PLASTIC (60219-1707-5) $0.0533 / ea $26.64 2020-06-24 Active

This pack has the lowest per-ea cost of the 2 priced pack sizes ($0.0533 NADAC).

In Medicaid, this is the most-dispensed pack of this product — about 60% of fills over the last four reported quarters. See all packs ↓

Pack size FAQ

What quantity is in NDC 60219-1707-01?
NDC 60219-1707-01 is a 100-count package — 100 tablet in 1 bottle, plastic.
What is the difference between NDC 60219-1707-01 and NDC 60219-1707-03?
Both are prednisone 10 mg Tablet — the drug itself is identical. NDC 60219-1707-01 is the 100-count package, while NDC 60219-1707-03 is the 100 tablets package.
What NDC number is used to bill for this package of prednisone 10 mg Tablet?
Bill NDC 60219-1707-01 — the 11-digit billing format is 60219170701. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

📄 Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⛔ Contraindications ⚠️ Warnings 🤒 Adverse Reactions 🔄 Drug Interactions 📦 How Supplied / Storage and Handling 📋 Description
🎯 Indications and Usage ~2 min read ▾

INDICATIONS Prednisone tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3.

Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6.

Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.

Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11.

Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement

⏱️ Dosage and Administration ~3 min read ▾

DOSAGE AND ADMINISTRATION The initial dosage of prednisone tablets may vary from 5 mg to 60 mg of prednisone per day depending on the specific disease entity being treated. In situations of less severity lower doses will generally suffice while in selected patients higher initial doses may be required. The initial dosage should be maintained or adjusted until a satisfactory response is noted.

If after a reasonable period of time there is a lack of satisfactory clinical response, prednisone tablets should be discontinued and the patient transferred to other appropriate therapy. IT SHOULD BE EMPHASIZED THAT DOSAGE REQUIREMENTS ARE VARIABLE AND MUST BE INDIVIDUALIZED ON THE BASIS OF THE DISEASE UNDER TREATMENT AND THE RESPONSE OF THE PATIENT. After a favorable response is noted, the proper maintenance dosage should be determined by decreasing the initial drug dosage in small decrements at appropriate time intervals until the lowest dosage which will maintain an adequate clinical response is reached.

It should be kept in mind that constant monitoring is needed in regard to drug dosage. Included in the situations which may make dosage adjustments necessary are changes in clinical status secondary to remissions or exacerbations in the disease process, the patient’s individual drug responsiveness, and the effect of patient exposure to stressful situations not directly related to the disease entity under treatment; in this latter situation it may be necessary to increase the dosage of prednisone tablets for a period of time consistent with the patient’s condition.

If after long-term therapy the drug is to be stopped, it is recommended that it be withdrawn gradually rather than abruptly. Multiple Sclerosis In the treatment of acute exacerbations of multiple sclerosis daily doses of 200 mg of prednisolone for a week followed by 80 mg every other day for 1 month have been shown to be effective. (Dosage range is the same for prednisone and prednisolone.) ADT ® (Alternate Day Therapy) ADT is a corticosteroid dosing regimen in which twice the usual daily dose of corticoid is administered every other morning.

The purpose of this mode of therapy is to provide the patient requiring long-term pharmacologic dose treatment with the beneficial effects of corticoids while minimizing certain undesirable effects, including pituitary-adrenal suppression, the Cushingoid state, corticoid withdrawal symptoms, and growth suppression in children. The rationale for this treatment schedule is based on two major premises: (a) the anti-inflammatory or therapeutic effect of corticoids persists longer than their physical presence and metabolic effects and (b) administration of the corticosteroid every other morning allows for re-establishment of more nearly normal hypothalamic-pituitary-adrenal (HPA) activity on the off-steroid day.

A brief review of the HPA physiology may be helpful in understanding this rationale. Acting primarily through the hypothalamus a fall in free cortisol stimulates the pituitary gland to produce increasing amounts of corticotropin (ACTH) while a rise in free cortisol inhibits ACTH secretion. Normally the HPA system is characterized by diurnal (circadian) rhythm.

Serum levels of ACTH rise from a low point about 10 pm to a peak level about 6 am. Increasing levels of ACTH stimulate adrenocortical activity resulting in a rise in plasma cortisol with maximal levels occurring between 2 am and 8 am. This rise in cortisol dampens ACTH production and in turn adrenocortical activity.

There is a gradual fall in plasma corticoids during the day with lowest levels occurring about midnight. The diurnal rhythm of the HPA axis is lost in Cushing’s disease, a syndrome of adrenocortical hyperfunction characterized by obesity with centripetal fat distribution, thinning of the skin with easy bruisability, muscle wasting with weakness, hypertension, latent diabetes, osteoporosis, electrolyte imbalance, etc. The same clinical findings of hyperadrenocorticis…

⛔ Contraindications 9 words ▾

CONTRAINDICATIONS Systemic fungal infections and known hypersensitivity to components.

⚠️ Warnings ~2 min read ▾

WARNINGS In patients on corticosteroid therapy subjected to any unusual stress, increased dosage of rapidly acting corticosteroids before, during, and after the stressful situation is indicated. Immunosuppression and Increased Risk of Infection Corticosteroids, including prednisone, suppress the immune system and increase the risk of infection with any pathogen, including viral, bacterial, fungal, protozoan, or helminthic pathogens. Corticosteroids can: Reduce resistance to new infections Exacerbate existing infections Increase the risk of disseminated infections Increase the risk of reactivation or exacerbation of latent infections Mask some signs of infection Corticosteroid-associated infections can be mild but can be severe and at times fatal.

The rate of infectious complications increases with increasing corticosteroid dosages. Monitor for the development of infection and consider prednisone withdrawal or dosage reduction as needed. Tuberculosis If prednisone is used to treat a condition in patients with latent tuberculosis or tuberculin reactivity, reactivation of tuberculosis may occur.

Closely monitor such patients for reactivation. During prolonged prednisone therapy, patients with latent tuberculosis or tuberculin reactivity should receive chemoprophylaxis. Varicella Zoster and Measles Viral Infections Varicella and measles can have a serious or even fatal course in non-immune patients taking corticosteroids, including prednisone.

In corticosteroid-treated patients who have not had these diseases or are non-immune, particular care should be taken to avoid exposure to varicella and measles: If a prednisone-treated patient is exposed to varicella, prophylaxis with varicella zoster immune globulin may be indicated. If varicella develops, treatment with antiviral agents may be considered. If a prednisone-treated patient is exposed to measles, prophylaxis with immunoglobulin may be indicated.

Hepatitis B Virus Reactivation Hepatitis B virus reactivation can occur in patients who are hepatitis B carriers treated with immunosuppressive dosages of corticosteroids, including prednisone. Reactivation can also occur infrequently in corticosteroid-treated patients who appear to have resolved hepatitis B infection. Screen patients for hepatitis B infection before initiating immunosuppressive (e.g., prolonged) treatment with prednisone.

For patients who show evidence of hepatitis B infection, recommend consultation with physicians with expertise in managing hepatitis B regarding monitoring and consideration for hepatitis B antiviral therapy. Fungal Infections Corticosteroids, including prednisone, may exacerbate systemic fungal infections; therefore, avoid prednisone use in the presence of such infections unless prednisone is needed to control drug reactions. For patients on chronic prednisone therapy who develop systemic fungal infections, prednisone withdrawal or dosage reduction is recommended.

Amebiasis Corticosteroids, including prednisone, may activate latent amebiasis. Therefore, it is recommended that latent amebiasis or active amebiasis be ruled out before initiating prednisone in patients who have spent time in the tropics or patients with unexplained diarrhea. Strongyloides Infestation Corticosteroids, including prednisone, should be used with great care in patients with known or suspected Strongyloides (threadworm) infestation.

In such patients, corticosteroid-induced immunosuppression may lead to Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia. Cerebral Malaria Avoid corticosteroids, including prednisone, in patients with cerebral malaria. Kaposi’s Sarcoma Kaposi’s sarcoma has been reported to occur in patients receiving corticosteroid therapy, most often for chronic conditions.

Discontinuation of corticosteroids may result in clinical improvement of Kaposi’s sarcoma. Prolonged use of corticosteroid…

🤒 Adverse Reactions 190 words ▾

ADVERSE REACTIONS Fluid and Electrolyte Disturbances Sodium retention Fluid retention Congestive heart failure in susceptible patients Potassium loss Hypokalemic alkalosis Hypertension Musculoskeletal Muscle weakness Steroid myopathy Loss of muscle mass Osteoporosis Tendon rupture, particularly of the Achilles tendon Vertebral compression fractures Aseptic necrosis of femoral and humeral heads Pathologic fracture of long bones Gastrointestinal Peptic ulcer with possible perforation and hemorrhage Pancreatitis Abdominal distention Ulcerative esophagitis Dermatologic Impaired wound healing Thin fragile skin Petechiae and ecchymoses Facial erythema Increased sweating May suppress reactions to skin tests Metabolic Negative nitrogen balance due to protein catabolism Neurological Increased intracranial pressure with papilledema (pseudotumor cerebri) usually after treatment Convulsions Vertigo Headache Endocrine Menstrual irregularities Development of Cushingoid state Secondary adrenocortical and pituitary unresponsiveness, particularly in times of stress, as in trauma, surgery or illness Suppression of growth in children Decreased carbohydrate tolerance Manifestations of latent diabetes mellitus Increased requirements for insulin or oral hypoglycemic agents in diabetics Ophthalmic Posterior subcapsular cataracts Increased intraocular pressure Glaucoma Exophthalmos Additional Reactions Urticaria and other allergic, anaphylactic or hypersensitivity reactions T o report SUSPECTED ADVERSE REACTIONS, contact Amneal Pharmaceuticals at 1-877-835-5472 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

🔄 Drug Interactions 150 words ▾

Drug Interactions The pharmacokinetic interactions listed below are potentially clinically important. Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance.

Therefore, the dose of corticosteroid should be titrated to avoid steroid toxicity. Corticosteroids may increase the clearance of chronic high dose aspirin. This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn.

Aspirin should be used cautiously in conjunction with corticosteroids in patients suffering from hypoprothrombinemia. The effect of corticosteroids on oral anticoagulants is variable. There are reports of enhanced as well as diminished effects of anticoagulants when given concurrently with corticosteroids.

Therefore, coagulation indices should be monitored to maintain the desired anticoagulant effect.

📦 How Supplied / Storage and Handling 160 words ▾

HOW SUPPLIED Prednisone Tablets USP, 10 mg are supplied as white to off-white, round, biconvex, uncoated tablets, scored on one side and debossed with “A48” on the other side. They are available as follows: Bottles of 100 (with child-resistant closure): NDC 60219-1707-1 Bottles of 500: NDC 60219-1707-5 Cartons of 100 (10 × 10 unit-dose tablets): NDC 60219-1707-3 Prednisone Tablets USP, 20 mg are supplied as white to off-white, round, biconvex, uncoated tablets, scored on one side and debossed with “AC72” on the other side.

They are available as follows: Bottles of 100 (with child-resistant closure): NDC 60219-1708-1 Bottles of 500: NDC 60219-1708-5 Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from moisture. Dispense in a tight, child-resistant container as defined in the USP.

Manufactured by: Amneal Pharmaceuticals Pvt. Ltd. Oral Solid Dosage Unit Ahmedabad 382213, INDIA Or Amneal Pharmaceuticals Pvt.

Ltd. Ahmedabad 382220, INDIA Distributed by: Amneal Pharmaceuticals LLC Bridgewater, NJ 08807 Rev. 07-2024-04

📋 Description 177 words ▾

DESCRIPTION Prednisone tablets, USP contain prednisone, USP which is a glucocorticoid. Glucocorticoids are adrenocortical steroids, both naturally occurring and synthetic, which are readily absorbed from the gastrointestinal tract. Prednisone, USP is a white to practically white, crystalline powder.

It is very slightly soluble in water; slightly soluble in alcohol, in chloroform, in dioxane, and in methanol. The chemical name for prednisone is 17,21-dihydroxypregna-1,4-diene-3,11,20-trione. Its molecular formula is C 21 H 26 O 5 and its molecular weight is 358.4 g/mole.

The structural formula is represented below: Prednisone tablets, USP are available in 2 strengths: 10 mg and 20 mg. Inactive Ingredients: Lactose monohydrate, magnesium stearate, microcrystalline cellulose, pregelatinized starch and sodium starch glycolate type A. Meets USP Dissolution Test 2.

ACTIONS Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs are primarily used for their potent anti-inflammatory effects in disorders of many organ systems. Glucocorticoids cause profound and varied metabolic effects.

In addition, they modify the body's immune responses to diverse stimuli. structure

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗
← 60219-1706-01 · Amneal 60219-1708-01 · Amneal →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.